Raffaele Di Francia

Summary

Publications

  1. ncbi Molecular diagnostics for pharmacogenomic testing of fluoropyrimidine based-therapy: costs, methods and applications
    Raffaele Di Francia
    Laboratory of Molecular Haematology, National Cancer Institute, Fondazione G Pascale IRCCS, Naples, Italy
    Clin Chem Lab Med 49:1105-11. 2011
  2. ncbi Expression of the brain transcription factor OTX1 occurs in a subset of normal germinal-center B cells and in aggressive Non-Hodgkin Lymphoma
    Daniela Omodei
    Centro di Ingegneria Genetica CEINGE Biotecnologie Avanzate, Naples, Italy
    Am J Pathol 175:2609-17. 2009
  3. ncbi Decision criteria for rational selection of homogeneous genotyping platforms for pharmacogenomics testing in clinical diagnostics
    Raffaele Di Francia
    Hematology Oncology and Stem Cell Transplantation Unit, National Cancer Institute, Fondazione G Pascale IRCCS, Naples, Italy
    Clin Chem Lab Med 48:447-59. 2010
  4. ncbi Nutrition in oncologic patients during antiblastic treatment
    Massimiliano Berretta
    Department of Medical Oncology, Centro di Riferimento Oncologico, National Cancer Institute, Aviano, Via Franco Gallini 2, 33081 Aviano PN, Italy
    Front Biosci 18:120-32. 2013

Collaborators

  • Antonio Pinto
  • Alessandro Cappellani
  • Stefano Casola
  • Claudio Orlando
  • Massimiliano Berretta
  • Daniela Omodei
  • Salvatore Berretta
  • Fabio Galvano
  • Umberto Tirelli
  • Rossella Fisichella
  • Maurizio Rupolo
  • Mariagrazia Michieli
  • Ferdinando Frigeri
  • Filippo Russo
  • Dario Acampora
  • Anna De Chiara
  • Pietro Mancuso
  • Valeria Severino
  • Antonio Simeone
  • Rosaria De Filippi

Detail Information

Publications4

  1. ncbi Molecular diagnostics for pharmacogenomic testing of fluoropyrimidine based-therapy: costs, methods and applications
    Raffaele Di Francia
    Laboratory of Molecular Haematology, National Cancer Institute, Fondazione G Pascale IRCCS, Naples, Italy
    Clin Chem Lab Med 49:1105-11. 2011
    ..00 per single polimorphism. On the basis of this information, the lab manager can evaluate the advantage and limitations, in terms of costs and applicability, of the most appropriate methods for diagnostics of 5-FU pharmacogenomics tests...
  2. ncbi Expression of the brain transcription factor OTX1 occurs in a subset of normal germinal-center B cells and in aggressive Non-Hodgkin Lymphoma
    Daniela Omodei
    Centro di Ingegneria Genetica CEINGE Biotecnologie Avanzate, Naples, Italy
    Am J Pathol 175:2609-17. 2009
    ..Furthermore, OTX1 expression in a subset of normal GC B cells carrying plasma cell markers suggests its possible contribution to terminal B-cell differentiation...
  3. ncbi Decision criteria for rational selection of homogeneous genotyping platforms for pharmacogenomics testing in clinical diagnostics
    Raffaele Di Francia
    Hematology Oncology and Stem Cell Transplantation Unit, National Cancer Institute, Fondazione G Pascale IRCCS, Naples, Italy
    Clin Chem Lab Med 48:447-59. 2010
    ..Based on the criteria proposed here, potential users may evaluate advantages and limitations of the various analytical platforms and identify the most appropriate platform according to their specific setting and diagnostic needs...
  4. ncbi Nutrition in oncologic patients during antiblastic treatment
    Massimiliano Berretta
    Department of Medical Oncology, Centro di Riferimento Oncologico, National Cancer Institute, Aviano, Via Franco Gallini 2, 33081 Aviano PN, Italy
    Front Biosci 18:120-32. 2013
    ..Based on this analysis, several nutritional proposals for cancer patients are suggested and the importance of good nutritional status in candidates for hematopoietic stem cell transplantation is highlighted...